|
Samuel Colella, Chairman
Samuel Colella has served as a member of our Board of Directors since July 2000. Mr. Colella is a managing director of Versant Ventures, a healthcare venture capital firm he co-founded in 1999, and has been a general partner of Institutional Venture Partners since 1984. Mr. Colella is a member of the Board of Directors of Alexza Pharmaceuticals, Inc., Genomic Health, Inc. and Jazz Pharmaceuticals, Inc. Mr. Colella received a B.S. in business and engineering from the University of Pittsburgh and an M.B.A. from Stanford University. |
Gajus Worthington, President, CEO, and Co-Founder Gajus V. Worthington is a Co-Founder of Fluidigm Corporation and has served as our President and Chief Executive Officer and a Director since our inception in June 1999. From May 1994 to April 1999, Mr. Worthington held various staff and management positions at Actel Corporation, a public semiconductor corporation. Mr. Worthington received a B.S. in Physics and an M.S. in Electrical Engineering from Stanford University. |
|
John A. Young John A. Young has been a member of our Board of Directors since March 2001. Mr. Young retired as President and Chief Executive Officer of Hewlett-Packard Company, a diversified electronics manufacturer, in October 1992, where he had served as President and Chief Executive Officer since 1978. Mr. Young received a B.S. in Electrical Engineering from Oregon State University and an M.B.A. from Stanford University. Mr. Young serves as a director of Affymetrix, Inc., Vermillion, Inc., a molecular diagnostics company, Perlegen Sciences, Inc., a drug development company, and Nanosys, Inc., a nanotechnology company.
|
|
Kenneth Nussbacher Kenneth J. Nussbacher has been a member of our Board of Directors since July 2003. He has been an Affymetrix fellow since 2000. From 1995 to 2000, Mr. Nussbacher was Executive Vice President of Affymetrix, Inc., a biotechnology company, and, from 1995 to 1997, he was also Chief Financial Officer of Affymetrix. Prior to joining Affymetrix, Mr. Nussbacher was Executive Vice President for business and legal affairs of Affymax Research Institute. He received a B.S. from Cooper Union and a J.D. from Duke University. Mr. Nussbacher is also a member of the Board of Directors of Symyx Technologies, Inc., a research and development solutions provider, and Xenoport, a biopharmaceutical company. |
|
Patrick S. Jones Patrick S. Jones has been a member of the Board of Directors since March 2011. Mr. Jones has been a private investor since March 2001. He currently sits on the boards of several leading public companies including Epocrates, a provider of clinical solutions to healthcare professionals and interactive services to the healthcare industry; Novell, Inc., a leading enterprise infrastructure software provider; Lattice Semiconductor Corporation, a fabless semiconductor company; and Openwave Systems, a telecom infrastructure software provider. From June 1998 to March 2001, Mr. Jones was the Senior Vice President and Chief Financial Officer of Gemplus International S.A. (now GEMALTO N.V.), a provider of solutions empowered by smart cards. Prior to Gemplus, from March 1992 to June 1998, he was Vice President and Corporate Controller at Intel Corp., a producer of microchips, computing and communications products. Prior to that, Mr. Jones served as Chief Financial Officer of LSI Logic, a semiconductor company. Evan Jones Evan Jones has served as a member of our Board of Directors since April 2011. Mr. Jones is currently Chairman of the Board of Campaign for Public Health, an organization dedicated to increasing the annual budget of the CDC (Centers for Disease Control and Prevention), and he also serves on the Board of Directors of Research!America. In the past, he has served as Chairman of the Board for Children's Research Institute and as a Board Member of the Children's National Medical Center. Mr. Jones is the Managing Member of jVen Capital, LLC, a life sciences investment company and was previously the co-founder, Chairman, and CEO of Digene Corporation, a publicly traded biotechnology company focused on women's health and molecular diagnostic testing. In all, Mr. Jones has more than 25 years of operating and investment experience in the life sciences industry. He received a B.A. from the University of Colorado and an M.B.A. from The Wharton School, University of Pennsylvania. |